AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03860116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care followup service
Description: When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
Study NCT03795025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training 3x10RM + no training
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
Study NCT03795025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training 6x10RM + no training
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
Study NCT03795025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3x10RM + 6x10RM
Description: Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
Study NCT02679989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Study NCT02679989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Energy Restriction
Description: Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
Study NCT00100841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00100841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00100841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00100841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00100841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00629876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen.
Study NCT03449992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate-rich beetroot juice
Description: Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
Study NCT03449992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink
Study NCT02865603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game
Description: PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
Study NCT02559726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography (TEE)
Study NCT02559726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography (TEE)
Study NCT02559726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) with gadolinium enhancement
Study NCT02559726 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI) without gadolinium enhancement
Study NCT02559726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D electrocardiographic mapping (ECM)
Study NCT02559726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D electrocardiographic mapping (ECM)
Study NCT03851146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LeY CAR T cells
Description: Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
Study NCT02268747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction.
Study NCT01463267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone or pillbox
Description: People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
Study NCT01463267 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-reminding
Description: As a comparison, the devices will collect medication taking information without providing reminders.
Study NCT01463267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-reminding
Description: As a comparison, the devices will collect medication taking information without providing reminders.
Study NCT00055861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00055861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00055861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01901861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg is given before meal ingestion
Study NCT01901861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given before meal ingestion
Study NCT03058367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (330mg)
Description: High dose capsules
Study NCT03058367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (165mg)
Description: Low dose capsules
Study NCT03058367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to verum capsules
Study NCT00693602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Chemotherapy
Study NCT02570139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
Study NCT02570139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConvaTec Sensi-Care Protective Barrier
Description: Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
Study NCT00445263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CORONAROGRAPHY
Description: standard procedure of coronarography
Study NCT02390063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.5T4
Description: A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
Study NCT02390063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.5T4
Description: A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Study NCT02390063 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA.5T4
Description: A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Study NCT02390063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide (50mg bd)
Study NCT02390063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Metronomic cyclophosphamide (50mg bd)
Study NCT04408027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual-Care Cognitive Behavioural Therapy
Description: The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
Study NCT02869113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98751 (Y65-110)
Description: 10 µL in one eye
Study NCT02869113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98751 (Y65-102)
Description: 10 µL in one eye
Study NCT02869113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98751 (Y65-106)
Description: 10 µL in one eye
Study NCT02869113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard shampoo mixture (Control)
Description: 10 µL in other eye
Study NCT02582164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Biomedical Engineering's Long-working distance OCT
Description: The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
Study NCT03925662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox with avastin
Description: Folfox with avastin only
Study NCT03925662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Folfox with avastin with mebendazole
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tPCS
Description: A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tPCS
Description: Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tPCS
Description: Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
Study NCT02497196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
Study NCT03645005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Guide (psychoeducation & self-management program)
Description: My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT03645005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Health (health education program)
Description: My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks.
Study NCT02845713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin, Diethylcarbamazine Albendazole (IDA)
Description: To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
Study NCT03503487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D informed consent
Description: Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
Study NCT03187041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets
Description: Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar).
Study NCT01763034 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: limb ischemic preconditioning
Description: use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
Study NCT02991703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pOpmètre®
Description: the pOpmètre® uses saturation sensors,
Study NCT02991703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sphygmocor
Description: the Sphygmocor uses applanation tonometry
Study NCT03413540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump
Description: Drop jump from step
Study NCT04189341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT04189341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified-thoracolumbar interfascial plane block
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT01376050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ML Scanner (MLS)
Description: Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
Study NCT01376050 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Placebo Laser has no therapeutic output emitted.
Study NCT03431480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Placental Cord Blood Mononuclear Cells
Description: Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
Study NCT02935777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Extract
Description: The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
Study NCT02935777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
Study NCT02666170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Study NCT04511949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)
Description: * The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies.
Study NCT00005005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH
Study NCT00005005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTH
Study NCT00053352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00053352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00053352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00053352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00005005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Study NCT02122081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT02122081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT02122081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0